DK0652002T3 - Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning - Google Patents

Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning

Info

Publication number
DK0652002T3
DK0652002T3 DK94307525T DK94307525T DK0652002T3 DK 0652002 T3 DK0652002 T3 DK 0652002T3 DK 94307525 T DK94307525 T DK 94307525T DK 94307525 T DK94307525 T DK 94307525T DK 0652002 T3 DK0652002 T3 DK 0652002T3
Authority
DK
Denmark
Prior art keywords
phenyl
cartilage degradation
aroylebenzothiophenes
drug
manufacture
Prior art date
Application number
DK94307525T
Other languages
English (en)
Inventor
Daniel Charles Williams
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0652002T3 publication Critical patent/DK0652002T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
DK94307525T 1993-10-15 1994-10-13 Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning DK0652002T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,531 US5418252A (en) 1993-10-15 1993-10-15 Method for inhibiting cartilage degradation

Publications (1)

Publication Number Publication Date
DK0652002T3 true DK0652002T3 (da) 2001-04-17

Family

ID=22477856

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94307525T DK0652002T3 (da) 1993-10-15 1994-10-13 Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning

Country Status (22)

Country Link
US (1) US5418252A (da)
EP (1) EP0652002B1 (da)
JP (1) JPH07188013A (da)
KR (1) KR950010887A (da)
CN (1) CN1053102C (da)
AT (1) ATE199642T1 (da)
AU (1) AU676375B2 (da)
CA (1) CA2118094A1 (da)
CZ (1) CZ253494A3 (da)
DE (1) DE69426855T2 (da)
DK (1) DK0652002T3 (da)
ES (1) ES2154669T3 (da)
GR (1) GR3035864T3 (da)
HU (1) HUT71249A (da)
IL (1) IL111291A (da)
NO (1) NO943873L (da)
NZ (1) NZ264672A (da)
PH (1) PH31316A (da)
PT (1) PT652002E (da)
RU (1) RU94037246A (da)
SI (1) SI0652002T1 (da)
ZA (1) ZA948028B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
CA2162586C (en) 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
CA2499819A1 (en) * 2002-09-30 2004-04-08 A/S Gea Farmaceutisk Fabrik Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
IL111291A0 (en) 1994-12-29
NO943873L (no) 1995-04-18
CN1053102C (zh) 2000-06-07
CN1106260A (zh) 1995-08-09
PT652002E (pt) 2001-06-29
CZ253494A3 (en) 1995-05-17
US5418252A (en) 1995-05-23
ES2154669T3 (es) 2001-04-16
DE69426855D1 (de) 2001-04-19
KR950010887A (ko) 1995-05-15
EP0652002A1 (en) 1995-05-10
AU7578994A (en) 1995-05-04
PH31316A (en) 1998-07-06
CA2118094A1 (en) 1995-04-16
ATE199642T1 (de) 2001-03-15
NO943873D0 (no) 1994-10-13
IL111291A (en) 1999-01-26
AU676375B2 (en) 1997-03-06
ZA948028B (en) 1996-04-15
HUT71249A (en) 1995-11-28
SI0652002T1 (en) 2001-06-30
HU9402957D0 (en) 1995-02-28
NZ264672A (en) 1997-06-24
EP0652002B1 (en) 2001-03-14
JPH07188013A (ja) 1995-07-25
DE69426855T2 (de) 2001-08-30
GR3035864T3 (en) 2001-08-31
RU94037246A (ru) 1996-11-10

Similar Documents

Publication Publication Date Title
DK0664126T3 (da) Hæmning af trombin
ES2157957T3 (es) Procedimientos para inhibir la endometriosis.
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
DK0659416T3 (da) Inhibering af seborE og acne
DK0652000T3 (da) Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et lægemiddel til inhibering af angiogenese og angiogene sygdomme
DK0652004T3 (da) Fremgangsmåder til behandling af resistente neoplasmer